Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2010-04-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
独立董事关于对外投资的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding the company's participation in a non-public share subscription of another company. It discusses the investment decision, compliance with laws and company rules, and the directors' approval. The document is short (697 characters) and focuses on a specific investment decision rather than comprehensive financial data or report. It does not contain financial statements or detailed financial performance data. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about an investment decision and independent directors' opinion, not a full financial report or other specific filing type.
2010-04-15 Chinese
第四届董事会第十次临时会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a board resolution announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the board's approval to participate in a non-public issuance of shares by another company. It details the board meeting date, voting results, and the investment plan. There is no financial report, earnings data, or detailed financial statements included. The document is an announcement of a board decision related to capital investment, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication or certification. Therefore, the classification is CAP with high confidence.
2010-04-15 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding its external investment in subscribing to a non-public issuance of A shares by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. It details the investment amount, the board's approval, the investment purpose, risks, and impact on the company. The document includes financial data of the investee company but does not contain comprehensive financial statements or detailed financial performance of the reporting company itself. It is not an annual or interim report, earnings release, or audit report. It is a specific announcement about a capital investment activity, specifically the company's participation in a non-public share subscription. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3667 characters, which is not very short, and it contains substantive information about the financing activity rather than just a notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2010-04-15 Chinese
关于收购北京普仁鸿医药销售有限公司部分股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of a partial equity stake in another company (Beijing Purenhong Pharmaceutical Sales Co., Ltd.) by Beijing Shuanglu Pharmaceutical Co., Ltd. It details the transaction overview, parties involved, financial data of the target company, contract terms, and strategic rationale. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is a capital transaction update about a share acquisition. The document is not a proxy statement, voting result, or management change announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2010-04-01 Chinese
关于召开2010年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a notice about convening the 2010 first extraordinary general meeting of shareholders for Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details about the meeting time, place, agenda (which is to review the proposal to change the 2009 financial statement audit institution), attendees, registration methods, and other procedural information. It does not contain any financial statements or results, nor is it a transcript or report of the meeting. It is a formal announcement to shareholders about the meeting itself, which fits the definition of a Proxy Solicitation & Information Statement (PSI) as it provides information and requests votes for the meeting.
2010-04-01 Chinese
关于变更公司2009年度财务报表审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the company's auditor for the 2009 annual financial statements. It mentions the merger of the original audit firm and the resulting change in the audit institution. The document references the 2009 annual financial statements audit but does not contain the audit report itself or detailed financial data. It also states that the change was approved by the board and will be voted on at a shareholders meeting. The document length is short (628 characters), and it serves as a formal announcement of the auditor change rather than the audit report or the annual report itself. Therefore, it fits best under Audit Report / Information (AR), which covers standalone audit reports and related announcements about audit firms, excluding full annual reports. FY 2009
2010-04-01 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.